-
公开(公告)号：UA107341C2
公开(公告)日：2014-12-25
申请号：UAA201111078
申请日：2010-02-17
Applicant: UCB PHARMA SA
-
公开(公告)号：DK1814915T3
公开(公告)日：2014-11-17
申请号：DK05803526
申请日：2005-11-16
Applicant: UCB PHARMA SA
Inventor： ADAMS RALPH , POPPLEWELL ANDREW GEORGE , RAPECKI STEPHEN EDWARD , TICKLE SIMON PETER
-
公开(公告)号：BRPI0809042A2
公开(公告)日：2014-09-16
申请号：BRPI0809042
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
公开(公告)号：EA020113B1
公开(公告)日：2014-08-29
申请号：EA200900040
申请日：2007-06-25
Applicant: UCB PHARMA SA
Inventor： RAPECKI STEPHEN EDWARD , POPPLEWELL ANDREW GEORGE , ADAMS RALPH
IPC: C07K16/24 , A61K39/395 , C12N15/13 , C12N15/20
Abstract: Визобретенииописанымолекулыантител, которыеобладаютспецифичностьюв отношенииантигенныхдетерминант IL-17, терапевтическиеприменениямолекулантители способыполученияуказанныхмолекулантител.
-
公开(公告)号：SG2014014708A
公开(公告)日：2014-05-29
申请号：SG2014014708
申请日：2010-02-17
Applicant: UCB PHARMA SA
Inventor： SHAW STEVAN GRAHAM , LAWSON ALASTAIR DAVID GRIFFITHS , NESBITT ANDREW MALCOLM , POPPLEWELL ANDREW GEORGE , SHPEKTOR DIANA , ZHANG YI
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
Patent Agency Ranking
公开(公告)号：HRP20140237T1
公开(公告)日：2014-05-09
申请号：HRP20140237
申请日：2014-03-13
Applicant: UCB PHARMA SA
Inventor： ADAMS RALPH , POPPLEWELL ANDREW GEORGE , RAPECKI STEPHEN EDWARD , TICKLE SIMON PETER
-
公开(公告)号：SI1814915T1
公开(公告)日：2014-04-30
申请号：SI200531833
申请日：2005-11-16
Applicant: UCB PHARMA SA
Inventor： ADAMS RALPH , POPPLEWELL ANDREW GEORGE , RAPECKI STEPHEN EDWARD , TICKLE SIMON PETER
-
公开(公告)号：EA018044B1
公开(公告)日：2013-05-30
申请号：EA200801427
申请日：2006-12-04
Applicant: UCB PHARMA SA
Inventor： GELINAS RICHARD EVAN , SINGHAL MITRA CHOUDHURY , ZHANG YI , POPPLEWELL ANDREW GEORGE , ADAMS RALPH
IPC: C07K16/24
Abstract: Визобретенииописанымолекулыантител, обладающиеспецифичностьюв отношенииантигенныхдетерминантИЛ-6, терапевтическиеприменениямолекулантители способыполученияуказанныхмолекулантител.
-
公开(公告)号：ZA201105500B
公开(公告)日：2012-10-31
申请号：ZA201105500
申请日：2011-07-26
Applicant: UCB PHARMA SA
Inventor： LAWSON ALASTAIR DAVID GRIFFITHS , NESBITT ANDREW MALCOLM , POPPLEWELL ANDREW GEORGE , SHPEKTOR DIANA , ZHANG YI , SHAW STEVAN GRAHAM
IPC: A61K20060101 , A61P20060101 , C07H20060101 , C07K20060101 , C12N20060101 , C12P20060101
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：PE20120211A1
公开(公告)日：2012-03-24
申请号：PE2011001494
申请日：2010-02-17
Applicant: UCB PHARMA SA
Inventor： LAWSON ALASTAIR DAVID GRIFFITHS , NESBITT ANDREW MALCOLM , POPPLEWELL ANDREW GEORGE , SHAW STEVAN GRAHAM , SHPEKTOR DIANA , ZHANG YI
Abstract: SE REFIERE A UN ANTICUERPO ANTAGONISTA QUE SE UNE A OX40 HUMANO QUE COMPRENDE: A) UNA CADENA PESADA CUYO DOMINIO VARIABLE COMPRENDE i) UN CDR-H1 QUE TIENE LA SECUENCIA SEQ ID Nº:1, ii) UN CDR-H2 QUE TIENE LA SECUENCIA SEQ ID Nº:2 O SEQ ID Nº:20, Y iii) UN CDR-H3 QUE TIENE LA SECUENCIA SEQ ID Nº:3; Y B) UNA CADENA LIGERA CUYO DOMINIO VARIABLE COMPRENDE i) UN CDR-L1 QUE TIENE LA SECUENCIA SEQ ID Nº:4 O SEQ ID Nº:21, ii) UN CDR-L2 QUE TIENE LA SECUENCIA SEQ ID Nº:5, Y iii) UN CDR-L3 QUE TIENE LA SECUENCIA SEQ ID Nº:6. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA SIENDO UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ASMA, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE CROHN
-
-
-
-
-
-
-
-
-
Search Results
161
records
(took 0.026 seconds)
